Nicergoline

Summary

Nicergoline (CHEMBL1372950) is an approved small molecule (ATC C04AE02); indicated across 6 conditions including cardiovascular disorder and anxiety.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C04AE02
• Indications: 6 conditions
• Clinical trials: 5
• Chemistry: 484.4 Da · C24H26BrN3O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1372950
Name	Nicergoline
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	34040
ATC	C04AE02
Molecular formula	C24H26BrN3O3
Molecular weight	484.4
InChIKey	YSEXMKHXIOCEJA-FVFQAYNVSA-N

SMILES: CN1C[C@@H](C[C@]2([C@H]1CC3=CN(C4=CC=CC2=C34)C)OC)COC(=O)C5=CC(=CN=C5)Br

IUPAC name: [(6aR,9R,10aS)-10a-methoxy-4,7-dimethyl-6a,8,9,10-tetrahydro-6H-indolo[4,3-fg]quinolin-9-yl]methyl 5-bromopyridine-3-carboxylate

Also known as: Cergodum, Circo-maren, Dilasenil, Duracebrol, Ergobel, Ergotop, FI-6714, Memoq, Nicergolent, Nicergolina, Nicergoline, Nilogrin

Patent coverage: 2,300 distinct patent families (7,573 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 7,568 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 20 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Lysine-specific demethylase 4E, Alpha-2A adrenergic receptor, D(1A) dopamine receptor, Thromboxane A2 receptor, Menin/Histone-lysine N-methyltransferase MLL, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1.

Bioactivity

ChEMBL activities: 13 potent at pChembl ≥ 5 of 20 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR1A	8.52	AC50	3	nM	CHEMBL_ACT_25164958
ADRA2A	7.37	AC50	42.6	nM	CHEMBL_ACT_25156363
KCNH2	6.89	AC50	130	nM	CHEMBL_ACT_25117514
DRD1	6.41	AC50	393.3	nM	CHEMBL_ACT_25115144
DRD3	6.19	AC50	640.8	nM	CHEMBL_ACT_25194458
ACHE	6.16	AC50	692.4	nM	CHEMBL_ACT_25142482
CHRM1	5.73	AC50	1855	nM	CHEMBL_ACT_25210156
OPRM1	5.62	AC50	2384	nM	CHEMBL_ACT_25158109
TDP1	5.3	Potency	5012	nM	CHEMBL_ACT_3936827
SLC6A4	5.14	AC50	7256	nM	CHEMBL_ACT_25151261
TBXA2R	5.12	AC50	7603	nM	CHEMBL_ACT_25197793
CHRM2	5.1	AC50	7930	nM	CHEMBL_ACT_25195670
HRH3	5.1	AC50	7914	nM	CHEMBL_ACT_25199466

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
Not specified	3
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients
NCT05551182	PHASE3	COMPLETED	Nicergoline Use in Dysphagia Patients
NCT07166835	Not specified	NOT_YET_RECRUITING	Exploring the Cognitive Benefits of a Blackcurrant-Based Supplement in Normobaric Hypoxia
NCT01009476	Not specified	COMPLETED	Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer’s Dementia Under Conditions of Daily Routine
NCT06689644	Not specified	COMPLETED	Effect of a Plant Based Nootropic on Perceptual Decision Making.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).